# Shield Post-Approval Study Protocol

> **NCT06880055** · — · RECRUITING · sponsor: **Guardant Health, Inc.** · enrollment: 3375 (estimated)

## Conditions studied

- Colo-rectal Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Shield Blood Test for colo-rectal cancer Screening

## Key facts

- **NCT ID:** NCT06880055
- **Lead sponsor:** Guardant Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2030-09-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 3375 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06880055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06880055, "Shield Post-Approval Study Protocol". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06880055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*